Silvia Jakob

Title: Innovations by Silvia Jakob in Opioid Treatment

Introduction

Silvia Jakob is a notable inventor based in Bernau, Germany. She has made significant contributions to the field of pharmaceuticals, particularly in the treatment of opioid-induced constipation. With a total of 2 patents, her work focuses on innovative methods and compositions that enhance patient care.

Latest Patents

Jakob's latest patents include a method and composition for the treatment of opioid-induced constipation. This invention involves a solid oral pharmaceutical dosage form that comprises an opioid receptor antagonist. The formulation is designed to provide effective treatment using an opioid antagonist equivalent to 24 mg of naloxone hydrochloride as a twice-daily formulation or 48 mg as a once-daily formulation. The pharmacokinetics of this formulation ensure a constant level of naloxone in the bloodstream, independent of the dosage frequency. Another significant patent is for naloxone single agent and multilayer tablets, which are designed for prolonged release of the active substance over an extended period, ensuring effective management of opioid-induced constipation.

Career Highlights

Throughout her career, Silvia Jakob has worked with various pharmaceutical companies, including Develco Pharma Schweiz AG and Algobate AG. Her experience in these organizations has contributed to her expertise in developing innovative pharmaceutical solutions.

Collaborations

Jakob has collaborated with notable professionals in her field, including Hélène Rey and Olaf Mundszinger. These collaborations have further enriched her research and development efforts.

Conclusion

Silvia Jakob's contributions to the pharmaceutical industry, particularly in the treatment of opioid-induced constipation, highlight her innovative spirit and dedication to improving patient outcomes. Her patents reflect a commitment to advancing medical science and enhancing therapeutic options for patients.